Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $13.49 billion. The enterprise value is $10.20 billion.
| Market Cap | 13.49B |
| Enterprise Value | 10.20B |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.34 million shares outstanding. The number of shares has decreased by -61.77% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 63.34M |
| Shares Change (YoY) | -61.77% |
| Shares Change (QoQ) | +587.82% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 60.93M |
Valuation Ratios
The trailing PE ratio is 11.84 and the forward PE ratio is 13.18.
| PE Ratio | 11.84 |
| Forward PE | 13.18 |
| PS Ratio | 4.18 |
| Forward PS | 0.51 |
| PB Ratio | 2.55 |
| P/TBV Ratio | 4.24 |
| P/FCF Ratio | 11.64 |
| P/OCF Ratio | 11.30 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.91, with an EV/FCF ratio of 8.80.
| EV / Earnings | 8.95 |
| EV / Sales | 3.16 |
| EV / EBITDA | 8.91 |
| EV / EBIT | 9.30 |
| EV / FCF | 8.80 |
Financial Position
The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.34 |
| Quick Ratio | 5.32 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | 0.12 |
| Interest Coverage | 59.70 |
Financial Efficiency
Return on equity (ROE) is 22.80% and return on invested capital (ROIC) is 13.34%.
| Return on Equity (ROE) | 22.80% |
| Return on Assets (ROA) | 11.54% |
| Return on Invested Capital (ROIC) | 13.34% |
| Return on Capital Employed (ROCE) | 18.83% |
| Revenue Per Employee | $1.20M |
| Profits Per Employee | $424,876 |
| Employee Count | 2,682 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 11.54 |
Taxes
In the past 12 months, Genmab has paid $183.25 million in taxes.
| Income Tax | 183.25M |
| Effective Tax Rate | 13.85% |
Stock Price Statistics
The stock price has decreased by -20.14% in the last 52 weeks. The beta is 0.82, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -20.14% |
| 50-Day Moving Average | 20.93 |
| 200-Day Moving Average | 21.50 |
| Relative Strength Index (RSI) | 41.06 |
| Average Volume (20 Days) | 1,565,061 |
Short Selling Information
The latest short interest is 2.23 million, so 0.37% of the outstanding shares have been sold short.
| Short Interest | 2.23M |
| Short Previous Month | 2.43M |
| Short % of Shares Out | 0.37% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.81 |
Income Statement
In the last 12 months, Genmab had revenue of $3.23 billion and earned $1.14 billion in profits. Earnings per share was $18.36.
| Revenue | 3.23B |
| Gross Profit | 3.07B |
| Operating Income | 1.10B |
| Pretax Income | n/a |
| Net Income | 1.14B |
| EBITDA | 1.14B |
| EBIT | 1.10B |
| Earnings Per Share (EPS) | $18.36 |
Balance Sheet
The company has $3.23 billion in cash and $143.00 million in debt, giving a net cash position of $3.08 billion or $48.67 per share.
| Cash & Cash Equivalents | 3.23B |
| Total Debt | 143.00M |
| Net Cash | 3.08B |
| Net Cash Per Share | $48.67 |
| Equity (Book Value) | 5.30B |
| Book Value Per Share | 83.61 |
| Working Capital | 3.28B |
Cash Flow
In the last 12 months, operating cash flow was $1.19 billion and capital expenditures -$35.09 million, giving a free cash flow of $1.16 billion.
| Operating Cash Flow | 1.19B |
| Capital Expenditures | -35.09M |
| Free Cash Flow | 1.16B |
| FCF Per Share | $18.29 |
Margins
Gross margin is 95.12%, with operating and profit margins of 33.97% and 35.27%.
| Gross Margin | 95.12% |
| Operating Margin | 33.97% |
| Pretax Margin | 40.94% |
| Profit Margin | 35.27% |
| EBITDA Margin | 35.43% |
| EBIT Margin | 33.97% |
| FCF Margin | 35.87% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 61.77% |
| Shareholder Yield | 61.77% |
| Earnings Yield | 8.45% |
| FCF Yield | 8.59% |
Analyst Forecast
The average price target for Genmab is $39.17, which is 91.07% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.17 |
| Price Target Difference | 91.07% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 66.41% |
| EPS Growth Forecast (5Y) | 57.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 9.65 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.65 |
| Piotroski F-Score | 5 |